BACKGROUND: The majority of patients randomized to percutaneous coronary intervention (PCI) in the Occluded Artery Trial (OAT) and its angiographic substudy, the Total Occlusion Study of Canada 2 (TOSCA-2) were treated with bare metal stents (BMS). We aimed to determine if stenting of the target occlusion in OAT with drug-eluting stents (DES) was associated with more favorable angiographic results and clinical outcome when compared with treatment with BMS. METHODS:TOSCA-2 DES was a prospective nonrandomized substudy that provided 1-year angiographic comparison of late loss and reocclusion in 25 patients treated with DES and in 128 treated with BMS. In addition, all PCI-assigned patients enrolled from the time when DES were first utilized were similarly categorized (DES n = 77, and BMS n = 386) and compared using the 3-year cumulative OAT primary combined endpoint of death, myocardial infarction, or Class-IV heart failure, as well as angina. RESULTS: In-segment late loss was 0.14 +/- 0.45 mm for DES and 0.75 +/- 0.86 mm for BMS (P < 0.001). Corresponding binary restenosis rates were 13.0% and 44.3% (P = 0.005). Occlusion at 1 year was observed in 4.0 and 12.1%, respectively (P = 0.23). The 3-year cumulative primary event rate was 13.8% with DES and 12.5% with BMS (hazard ratio 1.08, 99% confidence intervals 0.44, 2.64; P = 0.83). Angina over time occurred less frequently in the DES group (P = 0.01). CONCLUSIONS: Although the reduction of late loss and trend to reduction in reocclusion with the use of DES for PCI of persistently occluded IRA 3-28 days post myocardial infarction did not translate into a signal for reduction in death, reinfarction, or Class IV heart failure, DES use was associated with less angina over time. Further follow-up is warranted.
RCT Entities:
BACKGROUND: The majority of patients randomized to percutaneous coronary intervention (PCI) in the Occluded Artery Trial (OAT) and its angiographic substudy, the Total Occlusion Study of Canada 2 (TOSCA-2) were treated with bare metal stents (BMS). We aimed to determine if stenting of the target occlusion in OAT with drug-eluting stents (DES) was associated with more favorable angiographic results and clinical outcome when compared with treatment with BMS. METHODS: TOSCA-2 DES was a prospective nonrandomized substudy that provided 1-year angiographic comparison of late loss and reocclusion in 25 patients treated with DES and in 128 treated with BMS. In addition, all PCI-assigned patients enrolled from the time when DES were first utilized were similarly categorized (DES n = 77, and BMS n = 386) and compared using the 3-year cumulative OAT primary combined endpoint of death, myocardial infarction, or Class-IV heart failure, as well as angina. RESULTS: In-segment late loss was 0.14 +/- 0.45 mm for DES and 0.75 +/- 0.86 mm for BMS (P < 0.001). Corresponding binary restenosis rates were 13.0% and 44.3% (P = 0.005). Occlusion at 1 year was observed in 4.0 and 12.1%, respectively (P = 0.23). The 3-year cumulative primary event rate was 13.8% with DES and 12.5% with BMS (hazard ratio 1.08, 99% confidence intervals 0.44, 2.64; P = 0.83). Angina over time occurred less frequently in the DES group (P = 0.01). CONCLUSIONS: Although the reduction of late loss and trend to reduction in reocclusion with the use of DES for PCI of persistently occluded IRA 3-28 days post myocardial infarction did not translate into a signal for reduction in death, reinfarction, or Class IV heart failure, DES use was associated with less angina over time. Further follow-up is warranted.
Authors: Zaheer R Yousef; Simon R Redwood; Clifford A Bucknall; Alfred N Sulke; Michael S Marber Journal: J Am Coll Cardiol Date: 2002-09-04 Impact factor: 24.094
Authors: S R Mehta; S Yusuf; R J Peters; M E Bertrand; B S Lewis; M K Natarajan; K Malmberg; H Rupprecht; F Zhao; S Chrolavicius; I Copland; K A Fox Journal: Lancet Date: 2001-08-18 Impact factor: 79.321
Authors: P A Sirnes; S Golf; Y Myreng; P Mølstad; H Emanuelsson; P Albertsson; M Brekke; A Mangschau; K Endresen; J Kjekshus Journal: J Am Coll Cardiol Date: 1996-11-15 Impact factor: 24.094
Authors: J H Chesebro; G Knatterud; R Roberts; J Borer; L S Cohen; J Dalen; H T Dodge; C K Francis; D Hillis; P Ludbrook Journal: Circulation Date: 1987-07 Impact factor: 29.690
Authors: P Rubartelli; L Niccoli; E Verna; C Giachero; M Zimarino; A Fontanelli; C Vassanelli; L Campolo; E Martuscelli; G Tommasini Journal: J Am Coll Cardiol Date: 1998-07 Impact factor: 24.094
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Xavier Freixa; Vladimír Džavík; Sandra A Forman; James M Rankin; Christopher E Buller; Warren J Cantor; Witold Ruzyllo; Harmony R Reynolds; Gervasio A Lamas; Judith S Hochman Journal: Am Heart J Date: 2012-06 Impact factor: 4.749
Authors: Gerard Devlin; Harmony R Reynolds; Daniel B Mark; James M Rankin; Antonio C Carvalho; Carlos Vozzi; George Sopko; Paulo Caramori; Vladimir Džavík; Michael Ragosta; Sandra A Forman; Gervasio A Lamas; Judith S Hochman Journal: Am Heart J Date: 2011-01 Impact factor: 4.749
Authors: Adam H Skolnick; Harmony R Reynolds; Harvey D White; Venu Menon; Antonio C Carvalho; Aldo P Maggioni; Camille A Pearte; Luis Gruberg; Rudyney E U Azevedo; Erwin Schroeder; Sandra A Forman; Gervasio A Lamas; Judith S Hochman; Vladimír Džavík Journal: Am J Cardiol Date: 2011-12-14 Impact factor: 2.778
Authors: Nikolaos Konstantinidis; Michele Pighi; Ismail Dogu Kilic; Roberta Serdoz; Georgios Sianos; Carlo Di Mario Journal: Interv Cardiol Date: 2014-08